NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will deliver four poster presentations on its compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The conference will take place September 12-15, 2010 at the Boston Convention and Exhibition Center in Boston, MA.
The presentations will highlight new data developed from studies of NovaBay's Aganocide® family of compounds, which have shown to be highly effective against bacteria, including multi-drug resistant strains (e.g. MRSA), viruses and fungi in preclinical testing. Additionally, NovaBay's lead Aganocide, NVC-422, has recently demonstrated efficacy in a 129 patient dose-ranging Phase 2 clinical trial for the treatment of impetigo, a highly contagious skin infection affecting over 1.3 million patients in the U.S. annually.
Ron Najafi, chairman and CEO of NovaBay, said, "These presentations illustrate the anti-infective versatility of our Aganocide compounds and NovaBay's commitment to addressing the growing global crisis of antibiotic resistance by developing and commercializing an extensive pipeline of first-in-class, anti-infective compounds that are designed to treat infections without causing resistance."
NovaBay's pipeline of Aganocide compounds is being studied in numerous preclinical and clinical programs. Four (4) clinical trials of the company's lead Aganocide drug candidate are under way in impetigo, a highly contagious skin infection; urinary catheter-blockage and encrustation and associated infection; conjunctivitis (pink eye); and acne.
Poster session details are as follows:
Poster Title: V-420/444 -In Vitro Activity of N-Chlorotaurine (NCT), N-Monochloro-2,2-Dimethyltaurine (NVC-612) and N,N-Dichloro-2,2-Dimethyltaurine (NVC-422) against Influenza Viruses
Date: Sunday, Sept. 12
Time: 11:30 a.m. to 1:30 p.m.
Place: Exhibit Hall B1
Poster Title: K-2199/220 Efficacy of NVC-422, a Novel Derivative of N-Chlorotaurine, in Controlling Crystalline Proteus mirabilis Biofilm Formation on Urinary Catheters
Date: Wednesday, Sept. 15
Time: 9 a.m. to 11 a.m.
Place: Exhibit Hall B1
Poster Title: F1-2119-NVC-422: Towards Developing Preclinical Infected Tissue Models
Date: Wednesday, Sept. 15
Time: 9 a.m. to 11 a.m.
Place: Exhibit Hall B1
Poster Title: F1-2118/137- Anticoagulant Effects of N-Chlorotaurine and the Analogs N-Monochloro-2-2-Dimethyltaurine and N,N-Dichloro-2,2-Dimethyltaurine
Date: Wednesday, Sept. 15
Time: 9 a.m. to 11 a.m.
Place: Exhibit Hall B1
Early RSV vaccination in pregnancy provides best protection for newborns